Contrasting National Research (NASDAQ:NRC) and Iqvia (NASDAQ:IQV)

National Research (NASDAQ:NRC) and Iqvia (NYSE:IQV) are both business services companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Dividends

National Research pays an annual dividend of $0.76 per share and has a dividend yield of 1.3%. Iqvia does not pay a dividend. National Research pays out 73.1% of its earnings in the form of a dividend.

Analyst Ratings

This is a breakdown of recent ratings for National Research and Iqvia, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Research 0 1 0 0 2.00
Iqvia 0 2 15 1 2.94

Iqvia has a consensus price target of $164.49, indicating a potential upside of 15.14%. Given Iqvia’s stronger consensus rating and higher probable upside, analysts plainly believe Iqvia is more favorable than National Research.

Volatility and Risk

National Research has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Iqvia has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Valuation & Earnings

This table compares National Research and Iqvia’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
National Research $119.69 million 11.88 $30.05 million $1.04 55.00
Iqvia $10.41 billion 2.69 $259.00 million $5.12 27.90

Iqvia has higher revenue and earnings than National Research. Iqvia is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares National Research and Iqvia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
National Research 24.59% 124.11% 28.56%
Iqvia 2.31% 15.95% 4.91%

Insider & Institutional Ownership

36.0% of National Research shares are owned by institutional investors. Comparatively, 89.8% of Iqvia shares are owned by institutional investors. 4.5% of National Research shares are owned by insiders. Comparatively, 6.0% of Iqvia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Iqvia beats National Research on 11 of the 17 factors compared between the two stocks.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company’s clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.

Iqvia Company Profile

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.